Relay Therapeutics
Relay Therapeutics' revenue rose 53.4% to $15 million in fiscal 2025. Its operating margin was −1,971.6%, up from −3,722.1% a year earlier. Free cash flow was −$236 million. The diluted share count rose 20.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Relay Therapeutics does
Relay Therapeutics is a clinical-stage drug developer. It has no approved products and no product sales. It develops small-molecule medicines, meaning drugs in pill form, for cancer and for genetic diseases.
Its approach rests on a platform it calls Dynamo, which combines computer modeling and lab experiments to study how proteins move. The company says this helps it design drugs for protein targets that were hard or impossible to hit with older methods. It chooses targets where there is clear evidence linking a protein to a disease and where a diagnostic test can identify the patients who would benefit.
Its lead candidate is zovegalisib, also called RLY-2608. It is an inhibitor of a protein called PI3K alpha, and the company describes it as the first of its kind to block only certain mutated forms of the protein. Its main trial is in breast cancer and other solid tumors, where it is being tested with the drug fulvestrant and, in a three-drug combination, with a drug candidate from Pfizer. Relay pays for its research with money it raises and with deals with partners. It had 192 full-time employees at the end of 2025.
Its biggest risks, as it describes them
- It has never completed a large pivotal clinical trial, and its drug candidates may fail in trials.
- Its drugs use a new approach, which may bring added costs, regulatory hurdles or unexpected side effects.
- Testing its drugs in combination with other cancer treatments makes side effects harder to predict.
- Delays in enrolling patients or in getting regulatory approvals could hold up its drug candidates.
- It faces strong competition, and insurers may not cover or reimburse its drugs if approved.
Income statement
Relay Therapeutics lost money in fiscal 2025: a net loss of $276 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 280 | 152 | 144 | 124 | 84 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 40.1x | 16.0x | 25.4x | 15.9x | 22.6x |
| Quick ratio | 40.1x | 16.0x | 25.4x | 15.9x | 22.6x |
Cash flow
Projections
Project Relay Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Relay Therapeutics shares on the open market, and 5 insiders sold $127.9 million, $10.6 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Sanjiv PatelPresident and CEO, Director | Sold plan | 48,199 | $18.94 | $912,889 | Form 4 |
| Sep 8, 2026 | Thomas CatinazzoChief Financial Officer | Sold plan | 17,717 | $18.94 | $335,560 | Form 4 |
| Sep 8, 2026 | Donald A BergstromPresident, R&D | Sold plan | 8,530 | $18.97 | $161,814 | Form 4 |
| Aug 26, 2026 | Peter RahmerSee remarks | Sold plan | 4,508 | $20.03 | $90,295 | Form 4 |
| Aug 25, 2026 | Sb Investment Advisers (uk) Ltd10% owner | Sold | 6,000,000 | $19.40 | $116.4 million | Form 4 |
| Aug 17, 2026 | Sanjiv PatelPresident and CEO, Director | Sold plan | 48,199 | $20.33 | $979,886 | Form 4 |
| Aug 14, 2026 | Thomas CatinazzoChief Financial Officer | Sold plan | 17,717 | $19.74 | $349,734 | Form 4 |
| Jul 28, 2026 | Donald A BergstromPresident, R&D | Sold | 2,237 | $18.61 | $41,631 | Form 4 |
| Jul 28, 2026 | Thomas CatinazzoChief Financial Officer | Sold | 1,459 | $18.61 | $27,152 | Form 4 |
| Jul 28, 2026 | Peter RahmerSee remarks | Sold | 748 | $18.61 | $13,920 | Form 4 |
| Jul 7, 2026 | Sanjiv PatelPresident and CEO, Director | Sold plan | 48,199 | $19.58 | $943,736 | Form 4 |
| Jul 6, 2026 | Thomas CatinazzoChief Financial Officer | Sold plan | 17,717 | $18.69 | $331,131 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 558.1% | −2,570.3% | −1,482.6% |
| Altman Z'' | 5.96 | 5.07 | 2.96 |
| Accruals ratio | −4.3% | −10.3% | −5.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put Relay Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Relay Therapeutics | FY25 | 53.4% | −1,971.6% | −1,536.1% | — | — | — | |
| Arbutus Biopharma | FY25 | 128.2% | −271.0% | −281.4% | — | — | 3 | Compare |
| Janux Therapeutics | FY25 | −5.5% | −1,576.7% | −832.8% | — | — | — | Compare |
| Taysha Gene Therapies | FY25 | 17.3% | −1,130.7% | −960.1% | — | — | 4 | Compare |
| Roivant Sciences | FY25 | −71.6% | −6,235.7% | −9,183.5% | −62.6% | — | 1 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | 83 | 3 | 1 | 26 | 10 | 15 |
| Revenue growth | — | — | −96.3% | −54.4% | 1,749.8% | −60.8% | 53.4% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 70 | 100 | 173 | 246 | 330 | 319 | 261 |
| Operating income | −84 | −56 | −365 | −299 | −373 | −372 | −303 |
| Net income | −75 | −52 | −364 | −290 | −342 | −338 | −276 |
| Diluted EPS (US$) | −21.82 | −5.40 | −3.82 | −2.59 | −2.79 | −2.36 | −1.61 |
| Diluted shares (millions) | 4 | 43 | 95 | 112 | 123 | 143 | 172 |
| Cash flow | |||||||
| Cash from operations | −66 | −102 | −74 | −230 | −300 | −249 | −236 |
| Capital expenditure | 8 | 2 | 4 | 9 | 4 | 2 | 0 |
| Free cash flow | −74 | −104 | −78 | −239 | −304 | −251 | −236 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 25 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 4 | 32 | 48 | 56 | 86 | 94 | 62 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 42 | 448 | 280 | 152 | 144 | 124 | 84 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | 393 | 800 | 1,008 | 1,100 | 844 | 871 | 621 |
| Total liabilities | 36 | 36 | 111 | 150 | 92 | 94 | 54 |
| Shareholders' equity | −180 | 763 | 898 | 950 | 752 | 778 | 567 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | — | −67.5% | −12,040.2% | −21,670.9% | −1,460.1% | −3,722.1% | −1,971.6% |
| Net margin | — | −63.4% | −12,012.9% | −21,036.1% | −1,338.7% | −3,374.7% | −1,800.6% |
| Free cash flow margin | — | −126.3% | −2,571.1% | −17,273.9% | −1,191.7% | −2,509.5% | −1,536.1% |
| Rule of 40 (growth + FCF margin) | — | — | −2,667.4% | −17,328.3% | 558.1% | −2,570.3% | −1,482.6% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −18.0% | −43.8% | −31.4% | −40.2% | −44.1% | −41.1% |
| Return on assets | — | −8.8% | −40.2% | −27.6% | −35.2% | −39.4% | −37.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — |